Peptides · Peptide comparison
ARA-290 (Cibinetide) vs BPC-157
A peptide that awakens your body's natural repair system to heal damaged nerves and reduce pain
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
- Healing & Recovery
- Healing & Recovery
At a glance
Quick comparison
Efficacy
Benefit ratings
Nerve Regeneration
Pain Management
Tissue Protection
Primary Benefit
Secondary Benefit
Additional Benefit
Technical data
Compound specifications
ARA-290 (Cibinetide)
- Molecular formula
- C51H84N16O21
- Molecular weight
- 1257.31 g/mol
- Half-life
- Approximately 1-2 hours in circulation, but cellular effects last much longer
- Bioavailability
- Subcutaneous: ~100% (complete absorption); Intravenous: Immediate
- CAS number
- 1208243-50-8
BPC-157
- Molecular formula
- C62H98N16O22
- Molecular weight
- 1419.53 g/mol
- Half-life
- 4-6 hours
- Bioavailability
- ~100% (subcutaneous)
- CAS number
- 137525-51-0
Protocols
Dosing compared
ARA-290 (Cibinetide)
Subcutaneous
- 1 mgOnce daily · 28 daysLowest dose tested in the phase 2 sarcoidosis nerve study. A good starting point while watching how the body responds [1].
- 4 mgOnce daily · 28 daysThe 4 mg dose gave the strongest nerve-fiber regrowth and pain relief in the trial — better than the higher 8 mg dose [1][2].
- 8 mgOnce daily · 28 daysHighest daily dose studied in the sarcoidosis trial. It was safe but did not beat 4 mg for nerve outcomes [1].
Intravenous
- 2 mgThree times weekly · 4 weeksAn earlier sarcoidosis pilot gave 2 mg into a vein three times a week and saw improved nerve symptoms [6].
BPC-157
Subcutaneous
- 250 mcgOnce daily · 1-2 weeksA common starting amount in research practice, often injected near the injured area. BPC-157 has no human dose-finding trials, so doses come from animal studies and documented practice [1][2].
- 250-500 mcgTwice daily · 4-6 weeksCommonly used range for tissue and tendon recovery in research practice [1][3].
- 500 mcgTwice daily · 6-8 weeksUpper end used in practice for more demanding acute injuries [1][3].
Applications
Best suited for
ARA-290 (Cibinetide)
- Treating small fiber neuropathy
- ARA-290 (Cibinetide) is particularly well-suited for individuals focused on treating small fiber neuropathy. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Managing neuropathic pain from diabetes or sarcoidosis
- ARA-290 (Cibinetide) is particularly well-suited for individuals focused on managing neuropathic pain from diabetes or sarcoidosis. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Supporting nerve regeneration after injury
- ARA-290 (Cibinetide) is particularly well-suited for individuals focused on supporting nerve regeneration after injury. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
- Reducing chronic inflammation
- ARA-290 (Cibinetide) is particularly well-suited for individuals focused on reducing chronic inflammation. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
BPC-157
- Tendon and ligament injuries
- Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair [1][7]
- Gut healing
- IBS, leaky gut, ulcers, inflammatory bowel conditions [1][11] - derived from gastric juice, it has a natural affinity for digestive tissue [3][5]
- Muscle injuries
- Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression [8]
- Joint problems
- Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties [9][10]
- Post-surgical recovery
- Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms [2]
Safety profile
Side effects
ARA-290 (Cibinetide)
Common
- Injection Site Reactions
- Headache
- Dizziness
Uncommon
- Elevated Blood Pressure
- Fatigue
Serious
- Blood Clot Formation
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Research status
Safety & evidence
ARA-290 (Cibinetide)
- Evidence level
- Moderate human trials (Phase 1-2)
- FDA status
- Not FDA approved
- Safety overview
- ARA-290 is a synthetic innate repair receptor agonist that has completed Phase 2 clinical trials for small fiber neuropathy and is under active development. Animal toxicology studies show a good safety margin with no organ damage or cytotoxicity at doses far exceeding therapeutic levels. Early clinical data from Phase 2 trials demonstrate tolerability with mild injection site reactions and transient headache as primary concerns. However, immunogenicity remains a potential risk with repeated dosing of synthetic peptides, requiring anti-drug antibody monitoring. Long-term safety data beyond 12 weeks does not yet exist.
Contraindications
- Polycythemia vera or erythrocytosis
- Uncontrolled hypertension
- Pregnancy or breastfeeding
- Known hypersensitivity to peptides
- Concurrent use with certain cancer medications
BPC-157
- Evidence level
- Strong preclinical (extensive animal studies)
- FDA status
- Research compound
- Safety overview
- BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. [5] No FDA approval exists. [4][6] Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. [4][5] Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. [2][4] The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. [6][7] Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- Pregnancy
- Breastfeeding
- Active cancer
- History of cancer
Decision guide
Which is right for you?
ARA-290 (Cibinetide)
Choose ARA-290 (Cibinetide) if…
- Treating small fiber neuropathy
- Managing neuropathic pain from diabetes or sarcoidosis
- Supporting nerve regeneration after injury
- Reducing chronic inflammation
BPC-157
Choose BPC-157 if…
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health